AptamiR Therapeutics Inc is a modular biotechnology company based in Austin, TX, focused on developing safe and effective therapeutic agents to address unmet medical needs. Their mission is to cure cardiometabolic disorders such as obesity, dyslipidemia, diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD) without affecting brain functions, ultimately improving patients' quality of life.
Using the concept of One Drug-Multiple Targets, AptamiR Therapeutics aims to develop targeting microRNA Oligonucleotide Therapeutics (ONTs) that simultaneously modulate several target genes involved in complex diseases like obesity, MAFLD, and epithelial ovarian cancer. They have achieved proofs of efficacy for their first generation of microRNA-based ONTs in vitro and in vivo, and their goal for the next 24 months is to complete the pre-IND and IND phases for their new generation 2.5 active targeting miR-22-3p Antagomirs to treat metabolic pandemics and achieve pre-clinical selection of microRNA-based active targeting ONTs drug candidates to cure epithelial ovarian cancer.
Generated from the website